San Francisco startup Framework Therapeutics can be focusing on an oral, when-everyday GLP-one drug called GSBR-1290—the drug surpassed Wall Avenue’s expectations in June each time a mid-phase study confirmed typical weight loss of about six% and it designs to start out An additional mid-stage trial in direction of the end of this year—that f